Melanoma

>

Latest News

Dual Checkpoint Inhibition Increases Response Rates, Adverse Effects in Melanoma
Dual Checkpoint Inhibition Increases Response Rates, Adverse Effects in Melanoma

April 19th 2024

Patients with high-risk resectable melanoma treated with ipilimumab plus nivolumab had increased response rates compared with anti-PD1 monotherapy, though it was also associated with increased immune-related adverse effects.

Cancer Vaccine Plus Nivolumab/Ipilimumab Did Not Improve PFS in Metastatic Melanoma
Cancer Vaccine Plus Nivolumab/Ipilimumab Did Not Improve PFS in Metastatic Melanoma

March 8th 2024

Experience, Communication May Help Oncology Nurses Learn More About TIL Therapy in Advanced Melanoma
Experience, Communication May Help Oncology Nurses Learn More About TIL Therapy in Advanced Melanoma

February 22nd 2024

End-of-Life Immunotherapy Use Increasing in Advanced Melanoma, RCC, NSCLC
End-of-Life Immunotherapy Use Increasing in Advanced Melanoma, RCC, NSCLC

January 16th 2024

Oncology Drug Crash Course: Nivolumab Plus Relatlimab (Opdualag)
Oncology Drug Crash Course: Nivolumab Plus Relatlimab (Opdualag)

December 15th 2023

Latest CME Events & Activities

The Latest on Acute Lymphocytic Leukemia

View More

A Focus on Acute Myeloid Leukemia

View More

Updates in Myelodysplastic Syndromes

View More

Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma

View More

Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma

View More

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

8th Annual School of Nursing Oncology™

August 10, 2024

Register Now!

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

View More

Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

More News

© 2024 MJH Life Sciences

All rights reserved.